The Motley Fool
16 Nov 2026, 22:45 UTC · 2h ago
Dentsply Sirona: 3 Key Takeaways for Long-Term Investors
Impact · against what's priced in
Dentsply Sirona's downward revision of FY2026 sales and EPS guidance, driven by equipment weakness, creates a negative catalyst. The trade-off of short-term margins for long-term clinical education investments and the limited scale of the Wellspect segment fail to offset the immediate earnings deterioration.
- XRAY−0.70
No priced-in read yet
- In context
Management reduced full-year 2026 net sales guidance to $3.5 billion and adjusted EPS to $1.20-$1.30, reflecting a 7.6% quarterly revenue drop caused by weak equipment demand.
Read from the article alone

Search tags




